DIAGNOSIS AND TREATMENT OF NON-VARICEAL HEMORRHAGE FROM THE UPPER GASTROINTESTINAL TRACT: A VIEW OF A GENERAL PRACTITIONER


Дәйексөз келтіру

Толық мәтін

Аннотация

Gastrointestinal bleeding is one of the main causes of emergency hospitalization in developed countries. Strict adherence to the algorithm of action and continuity of care for bleeding at different stages of specialized medical care provides significantly better prognosis and survival in patients with this terrible syndrome. Effective treatment of non-variceal bleeding while minimizing the risk of relapse is possible only with combination of modern methods of endoscopic hemostasis and conservative treatment, including the use of high doses of proton pump inhibitors, which halves the risk of recurrent bleeding. Prophylactic eradication of Helicobacter pylori and/or subsequent prolonged parallel use of proton pump inhibitors in patients with suspected long-term use of aspirin and nonsteroidal anti-inflammatory drugs can significantly reduce the risk of ulcers and bleeding.

Әдебиет тізімі

  1. Chiu PW, Sung JJ. Acute nonvariceal upper gastrointestinal bleeding. Curr Opin Gastroenterol 2010;(5):425-28.
  2. Viviane A, Alan BN. Estimates of costs of hospital stays for variceal and nonvariceal upper gastrointestinal bleeding in the United States. Value Health 2008;11:1-3.
  3. Church NI, Palmer KR. Ulcers and nonvariceal bleeding. Endoscopy 2003;35(1):22-26.
  4. Kohn A, Ancona C, Belleudi V, et al. The impact of endoscopy and specialist care on 30-day mortality among patients with acute non-variceal upper gastrointestinal hemorrhage: an Italian population-based study. Dig Liver Dis 2010;42(9):629-34.
  5. Imhof M, Epstein S, Ohmann C, et al. Poor late prognosis of bleeding peptic ulcer. Langenbecks Arch Surg 2007;392(5):587-91.
  6. http://www.minzdravsoc.ru/docs/mzsr/letters/60
  7. Sostres C, Gargallo CJ, Arroyo MT, et al. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res. Clin Gastroenterol 2010;24(2):121-32.
  8. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;56:18-24.
  9. British Society of Gastroenterology Endoscopy Committee. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut 2002;51:1-6.
  10. Venerito M, Malfertheiner P. Interaction of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in gastric and duodenal ulcers. Helicobacter 2010;15(4):239-50.
  11. Gupta M, Eisen GM. NSAIDs and the gastrointestinal tract. Curr Gastroenterol Rep 2009;11(5):345-53.
  12. Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974;17:394-97.
  13. Scottish Intercollegiate Guidelines Network (SIGN). Management of acute upper and lower gastrointestinal bleeding. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN) 2008:57.
  14. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000;343:310-16.
  15. Palmer K. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut 2002;51(4):1-6.
  16. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-57.
  17. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004;99:1238-46.
  18. Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005;21:677-86.
  19. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:286-96.
  20. Lanas A, Artal A, Blas JM, et al. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol 1995;21(2):103-06.
  21. Green FW Jr, Kaplan MM, Curtis L, et al. Effect of acid and pepsin onblood coagulation and platelet aggregation: a possible contributor prolonged gastroduodenal muscosal hemorrhage. Gastroenterology 1978;74:38-43.
  22. Enns R, Andrews CN, Fishman M, et al. Description of prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicentre evaluation. Can J Gastroenterol 2004;18:567-71.
  23. Abraham E. Acid suppression in a critical care environment: state of the art and beyond. Crit Care Med 2002;30:349-50.
  24. Barkun AN, Herba K, Adam V, et al. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004;19:591-600.
  25. Goletti O, Sidoti F, Lippolis PV, et al. Omeprazole versus ranitidine plus somatostatin in the treatment of severe gastroduodenal bleeding: a prospective, randomized, controlled trial. Ital J Gastroenterol 1994; 26:72-74.
  26. Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding: results of a placebo-controlled multicenter study. Scand J Gastroenterol 1997;32:328-33.
  27. Lin HJ, Lo WC, Lee FY, et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998;158:54-58.
  28. Walt RP, Cottrell J, Mann SG, et al. Continuous intravenous famotidine for hemorrhage from peptic ulcer. Lancet 1992;340:1058-62.
  29. Labenz J, Peitz U, Leusing C, et al. Efficacy of primed infusion with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomized controlled study Gut 1997;40:36-41.
  30. Levine J, Leontiadis GI, Sharma VK, et al. Meta-analysis: the efficasy of intravenouse Н2-receptor antagonists in bleeding peptic ulcer. Alim Pharmacol Ther 2002;16:137-42.
  31. Rohss K, Bondarov P, Hallerback B, et al. Esomeprazole 40 mg intravenous (i.v.) provides a more pronounced reduction in intragastric acidity than pantoprazole 40 mg i.v. Gut 2004;53:A.104. And associated poster presented at UEGW 2004.
  32. Hartmann D, Eickhoff A, Damian U, et al. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. Eur J Gastroenterol Hepatol 2007;19:133-37.
  33. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding (a Randomized Trial). Ann Intern Med 2009;150:455-64.
  34. Rohss K, Gustafsson M, Lundin C, et al. Esomeprazole 40 mg administered intravenously (i.v.) provides better control of basal and stimulated gastric acid secretion than omeprazole 40 mg administered i.v. Gut 2004;53:A.106.
  35. Brown RE, Nandi J. Cost-effectiveness of high-dose intravenous esomeprazole in patients with peptic ulcer bleeding in the USA and Europe. Expert Rev Pharmacoecon Outcomes Res 2010;10(4):371-74.
  36. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44.
  37. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006;4:860-65.
  38. Hawkey CJ, Svedberg LE, Naesdal J, et al. Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies. Clin Drug Investig 2009;29(10):677-87.
  39. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010;49(8):509-33.
  40. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97.
  41. Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008;156(6):1080-88.
  42. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008;118(18):815, Abs 3999.
  43. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157(1):1-5.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2011

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>